Amylyx announces data in Muscle & Nerve demonstrating survival benefit

Home
news
Amylyx announces data in Muscle & Nerve demonstrating survival benefit

Amylyx announces data in Muscle & Nerve demonstrating survival benefit

FDA starts priority review of Orphazyme's therapy in Niemann Pick Disease

Emulate signs a strategic partnership with the FDA

Recent Posts

Prilenia enrolls first ALS patient in their Phase II / III study
Emulate unveils brain chip to enhance neuroinflammatory disease research and drug discovery which will support drug development for ALS
Prilenia shows positive effect on functional capacity in Huntigton’s Disease
Orphazyme submits marketing authorization in Europe for the treatment of Niemann Pick Disease
Emulate signs a strategic partnership with the FDA

ROBERT BROWN

Scientific Advisory Board